Questions About Cancer? 1-800-4-CANCER

Childhood Ependymoma Treatment (PDQ®)

Health Professional Version

Changes to This Summary (01/28/2015)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information About Childhood Ependymoma

Revised text to state that between 1975 and 2010, childhood cancer mortality decreased by more than 50% (cited Smith et al. as reference 3).

Treatment of Newly Diagnosed Childhood Ependymoma or Anaplastic Ependymoma

Added text to state that proton-beam radiation therapy provides a possible advantage for targeting the tumor while avoiding critical normal brain and neuroendocrine tissues, whether the tumor is supratentorial or infratentorial. Also added text to state that seventy children treated with involved-field, proton-beam radiation at Massachusetts General Hospital between 2000 and 2011 had 3-year local control of 83%, progression-free survival of 76%, and overall survival of 95%, with confirmation that subtotal resection was associated with an inferior outcome; data demonstrating an advantage in terms of intelligence, adaptive skills, neuroendocrine deficiencies, and other morbidities do not yet show an advantage over other forms of conformal radiation therapy (cited Macdonald et al. as reference 17).

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.

  • Updated: January 28, 2015